---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-23-000055"
form_type: "8-K"
ticker: "LEXX"
cik: "0001348362"
company_name: "Lexaria Bioscience Corp."
filed_at: "2023-01-17T23:59:59+00:00"
generated_at: "2026-06-20T14:36:07.231646+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lexaria CEO letter details FDA pre-IND success, new Japan client, no 2022 equity raise

## Summary
- FDA pre-IND meeting cleared path toward formal IND filing for DehydraTECH-CBD hypertension program; Phase 1(b) study expected in 2023.
- Signed first Asian client Premier Wellness Science with minimum quarterly payments totaling $4.53M over five years.
- Did not raise equity in 2022; management preserved capital; can survive most of 2023 without additional funding.
- Human nicotine study dosing began in December; results expected early 2023.
- Animal seizure study showed DehydraTECH-CBD competitive with Epidiolex; new R&D into dementia and diabetes underway.

## SEC filing metadata
- accession: 0001640334-23-000055
- form_type: 8-K
- ticker: LEXX
- cik: 0001348362
- company_name: Lexaria Bioscience Corp.
- filed_at: 2023-01-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348362/000164033423000055/0001640334-23-000055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348362/000164033423000055/lxrp_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-23-000055
- JSON: https://secwatch.observer/filing/0001640334-23-000055.json
- Plain text: https://secwatch.observer/filing/0001640334-23-000055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.